Yvette Drew
12PUBLICATIONS
73CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (12)
Sort by Publication Date:
|Apr 08, 2026
Phase Ib trial of SL-172154, a bispecific CD47 inhibitor and CD40 agonist Fc-fusion protein, in combination with mirvetuximab soravtansine or pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.Yvette Drew, Lucy Gilbert, Alejandro Martinez Bueno
|Mar 27, 2024
Targeted and Shallow Whole-Genome Sequencing Identifies Therapeutic Opportunities in p53abn Endometrial Cancers.Amy Jamieson, Juliana Sobral de Barros, Dawn R Cochrane
|Nov 08, 2023
Olaparib plus Durvalumab, with or without Bevacizumab, as Treatment in PARP Inhibitor-Naïve Platinum-Sensitive Relapsed Ovarian Cancer: A Phase II Multi-Cohort Study.Yvette Drew, Jae-Weon Kim, Richard T Penson
|Nov 26, 2022
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling.Hannah L Smith, Elaine Willmore, Asima Mukhopadhyay
|Aug 12, 2022
The Role of ATR Inhibitors in Ovarian Cancer: Investigating Predictive Biomarkers of Response.Alice Bradbury, Frank T Zenke, Nicola J Curtin
|Apr 28, 2021
Pharmacokinetics and safety of rucaparib in patients with advanced solid tumors and hepatic impairment.Nikolay Grechko, Viera Skarbova, Monika Tomaszewska-Kiecana
Pageof 2
Frequent Collaborators
3 joint publications
Nicola J Curtin
2 joint publications
David S Hong
2 joint publications
Timothy A Yap
2 joint publications
Rebecca S Kristeleit
2 joint publications
Susana Banerjee
2 joint publications
Ruth Plummer
1 joint publications
Ignace Vergote
1 joint publications
Robert L Coleman
1 joint publications
Lini Pandite
1 joint publications
Susana Miranda
